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Abstract
Background: Systemic lupus erythematosus is an age- and gender-associated autoimmune disorder.
Previous studies suggested that defects in the hypothalamic/pituitary axis contributed to systemic lupus
erythematosus disease progression which could also involve growth hormone, insulin-like growth factor-
1 and somatostatin function. This study was designed to compare basal serum growth hormone, insulin-
like growth factor-1 and somatostatin levels in female systemic lupus erythematosus patients to a group
of normal female subjects.
Methods: Basal serum growth hormone, insulin-like growth factor-1 and somatostatin levels were
measured by standard radioimmunoassay.
Results: Serum growth hormone levels failed to correlate with age (r2 = 3.03) in the entire group of
normal subjects (i.e. 20 – 80 years). In contrast, serum insulin-like growth factor-1 levels were inversely
correlated with age (adjusted r2 = 0.092). Of note, serum growth hormone was positively correlated with
age (adjusted r2 = 0.269) in the 20 – 46 year range which overlapped with the age range of patients in the
systemic lupus erythematosus group. In that regard, serum growth hormone levels were not significantly
higher compared to either the entire group of normal subjects (20 – 80 yrs) or to normal subjects age-
matched to the systemic lupus erythematosus patients. Serum insulin-like growth factor-1 levels were
significantly elevated (p < 0.001) in systemic lupus erythematosus patients, but only when compared to the
entire group of normal subjects. Serum somatostatin levels differed from normal subjects only in older (i.e.
>55 yrs) systemic lupus erythematosus patients.
Conclusions: These results indicated that systemic lupus erythematosus was not characterized by a
modulation of the growth hormone/insulin-like growth factor-1 paracrine axis when serum samples from
systemic lupus erythematosus patients were compared to age- matched normal female subjects. These
results in systemic lupus erythematosus differ from those previously reported in other musculoskeletal
disorders such as rheumatoid arthritis, osteoarthritis, fibromyalgia, diffuse idiopathic skeletal hyperostosis
and hypermobility syndrome where significantly higher serum growth hormone levels were found.
Somatostatin levels in elderly systemic lupus erythematosus patients may provide a clinical marker of
disease activity in these patients.
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Systemic lupus erythematosus (SLE) is the protean
autoimmune disorder with strong familial penetrance.
Immunologically, SLE is characterized by aberrations in T
cell and B cell function [1,2], over-production of autoan-
tibodies directed principally against nuclear antigens [3]
as well as other tissue antigens, and deficiences in the
complement system [4]. SLE is predominantly a disease of
young females with peak incidence occuring between 20
and 40 yrs with a female to male ratio of 6–10:1 [5].
Although many of the principal pathophysiological
changes associated with SLE indicate organ involvement
consistent with vascular inflammation and immune com-
plex deposition [6], several prominent SLE-related patho-
logic findings suggest systemic disturbances consistent
with metabolic abnormalities [7]. However, surrogate
blood or serum markers of systemic dysfunction such as
erythyrocyte sedimentation rate and C-reactive protein
levels, although frequently elevated in SLE compared to
normal subjects are often uninformative and unreliable as
surrogate markers of SLE disease activity [7].
We have shown that diverse rheumatic and musculoskel-
etal disorders, including osteoarthritis (OA) [8-12], dif-
fuse idiopathic skeletal hyperostosis (DISH) [12,13] and
hypermobility syndrome [14] as well as fibromyalgia [15]
were characterized, in part, by elevated serum growth hor-
mone levels. Growth hormone was also found seques-
tered in erythrocytes in OA and DISH patients at levels
that significantly exceeded serum growth hormone levels
[16] suggesting a putative mechanism by which "toxic"
levels of growth hormone could be confined, or in cases
of vascular inflammation, transported to joint synovial
fluid or peripheral end-organs [11,16]. Further, medical
therapy of OA and DISH principally with non-steroidal
anti-inflammatory drugs (NSAIDs) which resulted in pain
suppression and reduced stiffness as well as improved
range of motion correlated with lower serum growth hor-
mone levels consistent with levels found in normal sub-
jects [10,13]. More recently, we showed that symptomatic
rheumatoid arthritis (RA) patients were also characterized
by elevated serum growth hormone levels [17], but treat-
ment of RA with prednisone failed to significantly lower
serum growth hormone levels.
Insulin-like growth factor-1 (IGF-1) synthesis is coupled
to growth hormone via its capacity to stimulate hepato-
cyte IGF-1 production [11]. In several rheumatic and mus-
culoskeletal disorders, elevated serum growth hormone
was correlated with elevated IGF-1 levels [9,11,13,14]
with OA [8-10,12] and RA [17] being notable exceptions.
In the case of OA, IGF-1 levels are significantly lower com-
pared to normal control subjects [8-10,12]. However,
medical therapy of OA principally with NSAIDs resulted
in growth hormone and IGF-1 levels approaching normal
[10] whereas in DISH patients treated with NSAIDs,
reduced serum growth hormone levels failed to result in
concomitant changes in IGF-1 [13].
Somatostatin is a 14 amino acid polypeptide whose prin-
cipal function is to regulate growth hormone release from
the pituitary [18]. Elevated serum and synovial fluid
somatostatin levels have been associated with inflamma-
tory responses [19] most notably in RA [20]. A recent
study showed that patients with symptomatic RA were, in
part, characterized by a skewed upward serum growth
hormone to somatostatin ratio [17].
The present study was performed to determine the extent
to which serum growth hormone, IGF-1 and somatostatin
levels were modulated in patients with SLE. A linear
regression analysis was performed to determine the rela-
tionship between age and serum growth hormone and
IGF-1 levels in a group of normal female subjects so that
these values could be employed for comparison to a
group of predominantly young, female SLE patients.
Methods
All studies were performed at University Hospitals of
Cleveland (UHC) and the Wade Park Veterans Adminis-
tration Medical Center (VAMC), Cleveland, Ohio. The
UHC and VAMC Institutional Review Boards approved
the study design with the research protocol, which
included informed consent, being in keeping with the
Declaration of Helsinki. Normal subjects and SLE patients
were all volunteers. SLE Patients met the clinical and lab-
oratory criteria for the diagnosis of SLE according to pre-
viously published classifications [21]. Patients with co-
morbid conditions such as diabetes mellitus or hypergly-
cemia were excluded from the normal subject group as
was any normal individual with evidence for rheumatic
disorders in family members. This information was
obtained by questioning potential normal subjects.
Blood drawn by venipuncture was clotted at room tem-
perature, centrifuged, serum aliquots separated and stored
at -70°C until assayed. Blood samples were generally col-
lected during an identical 3–4 hr morning period to nor-
malize the potential contribution of growth hormone
pulses and serum glucose levels to serum growth hor-
mone determinations [8-10]. Serum samples were
included for serum growth hormone, IGF-1 or somatosta-
tin determinations only if glucose levels measured by the
highly sensitive hexokinase assay [8-10] were between 65
and 135 mg/dl attained either by overnight fasting or a
fast of at least 4 hours or more. Insulin levels were meas-
ured as previously described [8-10]. An insulin level in the
range of 5–27 µU/ml was considered normal.Page 2 of 8
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mined by standard radioimmunoassay (RIA) (INCSTAR,
Stillwater, MN) as previously described [8-10]. The lower
limit of detection for serum growth hormone by the RIA
was 0.4 ng/ml [8-10]. Serum growth hormone levels in
samples falling at or below the lower limit of detection
were excluded from the statistical analysis. Basal somato-
statin levels in serum of 112 normal subjects and 55 SLE
patients stratified by age (i.e. <45, between 45 and 55 yrs
and >55 yrs of age) were separately measured by RIA [17].
The 2-tailed T-test was employed to analyze the differ-
ences in means of serum growth hormone, IGF-1 and
somatostatin concentrations in groups of unequal size
where p < 0.05 was significant. The population sample
size was sufficient to detect a 20% difference in serum
growth hormone and IGF-1 levels between control sub-
jects and SLE patients and a 15% difference in serum
somatostatin levels. The relationship between serum
growth hormone and IGF-1 levels as a function of age was
analyzed from scatter plots by linear regression analysis
employing SPSS 11.1 (SPSS, Inc., Chicago, IL) and Sigma-
Plot 8.0 (SPSS, Inc.) to calculate the adjusted r2-value and
regression line, respectively.
Results and discussion
Glucose and insulin concentration was determined in
serum from normal female subjects and from patients
with SLE. No normal female subjects were excluded from
the study as a result of detecting hyperglycemia or hyper-
insulinemia However, 2 SLE patients were excluded from
the statistical analysis on this basis (data not shown).
Over the course of this study, SLE patients received medi-
cal therapy with NSAIDs, prednisone (10–60 mg/day),
hydroxychloroquine sulfate or methotrexate as well as
combinations of these drugs. No SLE patients were treated
with azathioprine or cyclophosphamide during this
study.
Previously it was shown that basal serum growth hor-
mone levels among normal male and female subjects did
not significantly differ on the basis of age [16]. As noted,
SLE has a high female to male prevalence ratio and is pre-
dominant in young females between 20 and 40 yrs of age
[5,21]. Thus, it was critical to determine the extent to
which serum growth hormone and IGF-1 differed among
female normal subjects on the basis of age. Serum growth
hormone levels did not correlate with age in normal
female subjects between the ages of 20 and 80 (Figure 1A).
However, a strong inverse correlation between age and
IGF-1 levels (adjusted r2 = 0.269) in this group of normal
female subjects was found (Figure 1B).
In contrast to the results obtained from basal serum
growth hormone measurements in the entire normal
female subject population (Figure 1A), a strong direct cor-
relation (adjusted r2 = 0.092) between age (age, 30.8 ± 7.0,
mean ± SD; 95% confidence, 3.74) and basal serum
growth hormone levels in the young female normal sub-
jects was found (Figure 2A). However, the correlation
between age and basal serum growth hormone levels was
weak in the older (age, 60.6 ± 9.4; mean ± SD; 95% con-
fidence, 3.29) normal female subjects (Figure 2B).
Based on the above considerations, basal serum growth
hormone and IGF-1 concentration was determined in
study groups subdivided by age in normal female subjects
and these values compared with basal serum growth hor-
mone and IGF-1 levels in SLE patients. The results showed
that SLE was not characterized by elevated serum growth
hormone whether or not all normal female subjects or
age-matched normal female subjects were employed as
the comparison group (Table 1). Serum IGF-1 levels were
significantly lower in the normal female subject group
compared to SLE patients (Table 1), but there was no sig-
nificant difference if serum IGF-1 levels in the SLE group
were compared to serum IGF-1 levels in the age-matched
normal female group (Table 1).
A trend towards elevated somatostatin levels in normal
subjects as a function age was previously found [17]. In
the present study, there was also a trend towards elevated
serum somatostatin levels in the <45 yr old SLE patient
group or 45 – 55 yr old group compared to their age-
matched normal counterparts (Table 1). However, a sig-
nificant difference was found only in the older (>55 yrs)
SLE patients compared to their age-matched control coun-
terparts (Table 1).
The results of the present study emphasized the critical
requirement to control for age and gender when basal
serum growth hormone and IGF-1 levels in normal sub-
jects are compared to patients with autoimmune muscu-
loskeletal diseases which, like SLE, are characterized by a
strong age and gender association.
Several studies from our laboratory have consistently
shown basal serum growth hormone to be higher in
females than in males [8,9,14]. One study, in particular,
examined the correlation between age, gender and race
with basal serum growth hormone and concluded that, in
general, older Causcasian women had slightly higher
growth hormone levels compared to older African-Ameri-
can women [8]. However, in that study (8) no statistical
differences were shown when serum growth hormone lev-
els in young Caucasian women (age, 28 ± 6; mean ± SD)
were compared to serum growth hormone levels in Afri-
can-American women (age, 34 ± 10). This finding isPage 3 of 8
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Linear regression analysis. Serum growth hormone levels (Panel A) or serum IGF-1 levels (Panel B) were plotted as a function 
of age in a normal female subject group. The results indicated that while serum growth hormone levels were not correlated 
with age (adjusted r2 = 3.03), IGF-1 levels were inversely correlated to age (r2 = 0.269).Page 4 of 8
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Linear regression analysis. Serum growth hormone levels were plotted as a function of age in young (age range, 20 to 46 yrs) 
normal female subjects (Panel A) or older (age range, 47 to 80 yrs) normal female subjects (Panel B). The results indicated that 
serum growth hormone levels correlated with age (r2 = 0.092) only within the circumscribed group of younger normal female 
subjects.Page 5 of 8
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cases, SLE onset is prominent among young females dur-
ing their reproductive years, and African-American
women are over-represented in the SLE patient popula-
tion [21].
The present analysis also extends the results of previous
studies [8,9,14] and partially supports the conclusions of
Ghigo et al. [22] who showed that basal growth hormone
levels were similar in young and older individuals. Ghigo
et al. [22] further suggested that the somatotroph response
in young versus older individuals to the combined admin-
istration of arginine and growth hormone-releasing sub-
stance also did not vary with age.
In contrast, the present results do not support the conclu-
sions that growth hormone decreases as a function of age
as reported by Kelijman [23]. In fact, the results of the
present study showed a strong correlation between age
and serum growth hormone only in the circumscribed
young normal female (age 20 – 46 yrs) group (Figure 1A).
The decrease in basal serum IGF-1 levels with age (Figure
1B) confirmed previous studies by Hochberg et al. [24]
who studied patients with osteoarthritis of the knee as
well as earlier studies by Ghigo et al. [22] who reported a
significant difference in IGF-1 levels between young and
older individuals. Thus, it was not unexpected that basal
serum IGF-1 levels in SLE was significantly elevated when
compared to basal serum IGF-1 levels in the general pop-
ulation of normal subjects, but not so, when basal serum
IGF-1 levels from SLE patients were compared to their age-
matched counterparts (Table 1). In this regard, Bennett et
al. [25] also failed to find differences in serum IGF-1 levels
when normal subjects (age, 45.1 ± 8.6) were compared to
15 age-matched SLE patients (age, 42.5 ± 7.0).
The relationship between putative abnormalities in the
hypothalamic-pituitary axis, systemic disturbances and
SLE pathogenesis and progression remains conjectural. In
this regard, Rovensky et al. [26] found no correlation
between plasma prolactin, growth hormone, interleukin-
6, cortisol or C-reactive protein in adult SLE patients.
However, studies by Chikanza et al. [27] reached a differ-
ent conclusion. They suggested that a "pro-inflammatory
hormonal bias" existed in juvenile SLE which was identi-
cal to adult SLE. They also concluded that the role of the
neuroendocrine-immune system in adult SLE was, at the
present time, limited to deficiencies in prolactin. Of note,
two recent case reports suggested a link between growth
hormone and exacerbation of lupus nephritis in a male
teenager with SLE [28] as well as in juvenile SLE [29]
where when growth retardation treated with growth hor-
mone was terminated, clinical improvement in lupus
symptoms was observed. These findings suggested that
exogenously-administered growth hormone may result in
"toxic" levels of growth hormone accompanied by lupus
"flares" with progressive autoimmune dysfunction.
A recent study from this laboratory showed that the
growth hormone to somatostatin ratio was skewed
upward in patients with RA [17]. In the present study,
somatostatin levels in the age groups encompassing the
average age of the SLE patients were not different from
than of normal subjects (Table 1). Although previous
studies have suggested that somatostatinergic activity
Table 1: Serum Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1) and Somatostatin (SOM) levels in normal female subjects 
and Systemic Lupus Erythematosus (SLE) patients
Group Age (yrs)* GH ng/ml)* IGF-1 (nM/L)* SOM (pg/ml)* p-value
All Normals (35) 57.1 ± 13.1 1.17 ± 0.40 14.9 ± 3.6
(77) <45 25.2 ± 11
(17) 45–55 32.6 ± 12
(18) >55 36.2 ± 10
Age- Matched 
Normals (18)
30.8 ± 7.1** 1.58 ± 1.16** 25.0 ± 7.3†
SLE (17) 35.9 ± 8.6† 1.45 ± 0.88† 22.8 ± 7.1**
(22) < 45 29.8 ± 12 P > 0.05
(12) 45–55 35.4 ± 14 P > 0.05
(21) >55 29.9 ± 9 P < 0.05
AMNv.SLE **P > 0.05 **P > 0.05 **P > 0.05
ANv.SLE †P < 0.001 †P > 0.05 †P < 0.001
• Mean ± SD
• N: number of samples
AMN: age-matched normal subjects
AN: all normal subjects
SLE: systemic lupus erythematosus patientsPage 6 of 8
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does not support that view (at least from measurements of
basal somatostatin levels) as lower somatostatin levels in
the older SLE patients reached statistical significance
when compared to age-matched controls with the caveat
that the present study did not relate changes in somatosta-
tin to SLE disease activity.
Although somatostatin may alter growth hormone effects
and immune responses in chronic autoimmune diseases,
the relationship between somatostatin and "specific"
somatostatin receptor (sSR) in SLE remains to be eluci-
dated. In this regard, van Hagen [30] showed that 97% of
patients with sarcoidosis, 100% of patients with tubercu-
losis or Wegener's granulomatosis, 75% of patients with
Sjogren's syndrome but only 50% of SLE patients exhib-
ited sSRs on mitogen-activated human peripheral lym-
phocytes compared to 97% in normal individuals. Of
note, somatostatin receptor levels appeared to be unre-
lated to disease progression or remission. In the present
study, a trend towards reduced serum somatostatin levels
was seen only in the older SLE patients (Table 1). As func-
tional somatostatin may change in autoimmunity and
result in altered growth hormone release, reduced soma-
tostatin levels could also influence basal levels of growth
hormone in elderly SLE patients. Thus, changes in soma-
tostatin could be one of several environmental stress
factors resulting in the progression of clinically active dis-
ease in older SLE patients [31].
The therapeutic implications and diagnostic utility of
serum growth hormone, IGF-1 and somatostatin meas-
urements in SLE as well as in other musculoskeletal disor-
ders appears central to assigning a role for these factors in
disease progression. Serum growth hormone remained
elevated in some DISH and OA patients where clinical
symptoms were significant [9,11,12]. Thus, single serum
growth hormone determinations appear to accurately
reflect a pattern of serum growth hormone levels associ-
ated with these clinical disorders. Further, improvement
in the clinical symptoms in OA and DISH patients with
medical therapy [10,13] resulted in a sustained reduction
in serum growth hormone levels reaching levels compara-
ble to those found in normal subjects. Although longitu-
dinal measurements of serum somatostatin in SLE and
other rheumatic diseases have not yet been performed,
reduced somatostatin levels appear to be most strongly
associated with joint inflammation (as was seen in RA)
[17] as well as in older patients (>55 yrs) with the inflam-
matory complications of knee OA (Denko and Malemud,
submitted). Thus, it could be informative if elevated
somatostatin levels correlated with clinical improvement
in SLE patients.
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